Vivos Therapeutics (VVOS) Cash from Investing Activities Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -15.64% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | -514.42% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | -73.71% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -12.26% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 618.55% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 48.43% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 91.33% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 0.00% |
| 10 | Vivos Therapeutics | 4.96 Mn | 3.16 Mn | 2.95 Mn | 92.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85.25% |
| Dec 31, 2025 | -858.18% |
| Sep 30, 2025 | 143.23% |
| Jun 30, 2025 | -9,743.33% |
| Mar 31, 2025 | 19.21% |
| Dec 31, 2024 | 0.00% |
| Sep 30, 2024 | -24.68% |
| Jun 30, 2024 | 75.51% |
| Mar 31, 2024 | 47.75% |
| Dec 31, 2023 | 17.50% |
| Sep 30, 2023 | -54.00% |
| Jun 30, 2023 | 51.39% |
| Mar 31, 2023 | -140.83% |
| Dec 31, 2022 | 47.64% |
| Sep 30, 2022 | 76.85% |
| Jun 30, 2022 | 67.10% |
| Mar 31, 2022 | 54.20% |
| Dec 31, 2021 | -302.15% |
| Sep 30, 2021 | -3,498.80% |
| Jun 30, 2021 | -19,533.47% |